MEDIA ADVISORY, Oct. 20, 2006 (PRIMEZONE) --

 What:
 Ginger Graham, CEO of Amylin Pharmaceuticals (AMLN) will preside over
 the opening bell.

 Where:
 NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast
 Studio

 When:
 Monday October 23rd, 2006 at 9:30 a.m. EDT

 Contacts:
 Courtney Walker
 Vice President, Health
 Edelman
 (212) 704-8102
 Courtney.Walker@edelman.com

 NASDAQ MarketSite:
 Stephanie Lowenthal: (646) 441-5220

Feed Information:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Amylin Pharmaceuticals (AMLN):

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide.

Further information on Amylin Pharmaceuticals is available at www.amylin.com.